Development of antiviral inhibitor against dengue 2 targeting Ns3 protein: In vitro and in silico significant studies.

Dengue fever is a severe, widespread disease with more than 2 million diagnosed infections per year. The Dengue virus protease represents a cardinal target for prudent drug design. Among the four serotypes Dengue 2 is known for the occurrence of its frequent epidemics. The new compound inhibited the Dengue-2 in the low-micromolar range in cells. At the moment, protease inhibitors are not actively tried against dengue virus as therapeutic option. We have identified thiosemicarbazones derived phenyl-acetyl ketones as candidate for a novel class of protease inhibitors. Here, we report the selective and non-competitive inhibition of the Dengue virus serotype 2 in vitro and in silico. Molecular docking suggests binding at a specific active site. In addition to the docking assays, few techniques were developed to interpret these molecules's antiviral profile in vitro.

Dengue scenario: Chennai perspective-a six-year study (2009-2014).

Dengue is a public health problem with an increasing global incidence and geographic distribution in almost all tropical and subtropical countries, with a transition from epidemic to endemic occurrence. In this study, we report a six-year analysis (2009-2014) performed at the Department of Virology, King Institute of Preventive Medicine, Chennai, Tamil Nadu, India. Our data confirm earlier findings that dengue is highly endemic in Chennai. In the present study, 10,099 serum samples from suspected dengue cases were tested for IgM ELISA (NIV Capture) and IgG Panbio ELISA (Australia). Of these suspected cases 6,798 and 3,301 were pediatric and adult cases, respectively, and 1,927 (19.08 %) were confirmed serologically as dengue. Of these, 1,752 (25.7 %) and 175 (5.3 %) were pediatric and adult cases, respectively. The aim of this study was to highlight the occurrence of DHF and DSS, mainly among the pediatric population, in which the infection causes higher mortality and morbidity. The overall positivity was higher in the pediatric group than in the adults. Detection of both IgM and IgG positivity will be useful for monitoring infection rates, the disease spectrum, and the prevalence of the different serotypes, which will give us insight about the circulating serotypes and pathogenicity. These data will be valuable for providing an early warning to predict an impending epidemic leading to major clinical manifestations of DHF and DSS.

Antiviral activity of Thiosemicarbazones derived from α-amino acids against Dengue virus.

The endemicity and seasonal outbreaks of Dengue disease in most tropical and subtropical countries underscores an urgent need to develop effective prevention and control measures. Development of a Dengue vaccine, which is complicated by the Antibody Dependent Enhancement effect (ADE), a viral inhibitor, seems prudent as it would inhibit the spread of the virus. In vitro methods such as MTT assay and plaque formation unit reduction assays were employed for screening the viral inhibitory property of α-amino acid based Thiosemicarbazides. The results elicits that at concentrations not exceeding the maximum non cytotoxic concentration (MNCC), these compounds completely prevented Dengue virus infection in vero cells as indicated by the absence of cytopathic effects in a dose-dependent manner. The high potency of Bz-Trp-TSC against all four types of Dengue virus infection elevates Thiosemicarbazide as a lead antiviral agent for Dengue disease. Screening small molecules for antiviral activity against the most rapidly spreading mosquito-borne viral disease is being explored by several research groups. Our findings would help to augment the efforts to identify the lead compounds for antiviral therapy to combat the Dengue disease. J. Med. Virol. 89:546-552, 2017. © 2016 Wiley Periodicals, Inc.

Development and evaluation of flavi-immunoglobulin M capture enzyme-linked immunosorbent assay.

In this study, we report the evaluation of In-house flavi virus immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay (ELISA), which can be used as a screening test to determine the infecting flavivirus serotype over the current serological methods. A panel of 88 sera (inclusive of well characterized dengue, Japanese Encephalitis (JE) and West Nile virus (WNV) positive and negative samples tested and confirmed by commercial kit) was used for evaluation of the kit. The sensitivity and specificity of the In-house capture assay versus the commercial kit for the sero-diagnosis of dengue was 100% and 87% respectively, for JE IgM, it was found to be 90% and 100% respectively, and for West Nile it was 87.5% and 90.9%. Based on the study, we concluded that this flavivirus-serotyping ELISA provides rapid results and may be used as an accurate alternate to other serological tests for the specific diagnosis of flavivirus infections.